Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.

Lilly to bag Loxo Oncology for $8 billion

The acquisition would be the largest and latest in a series of transactions Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies. Loxo Oncology is developing a pipeline of targeted medicines focused on cancers that are uniquely dependent on single gene abnormalities that can be detected by genomic testing. For patients with cancers that harbor these genomic alterations, a targeted medicine could have the potential to treat the cancer with dramatic effect.

Loxo Oncology has a promising portfolio of approved and investigational medicines, including

  • LOXO-292, a first-in-class oral RET inhibitor that has been granted Breakthrough Therapy designation by the FDA for three indications, with an initial potential launch in 2020. LOXO-292 targets cancers with alterations to the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types, including certain lung and thyroid cancers as well as a subset of other cancers.
  • LOXO-305, an oral BTK inhibitor currently in Phase I/II. LOXO-305 targets cancers with alterations to the Bruton's tyrosine kinase (BTK), and is designed to address acquired resistance to currently available BTK inhibitors. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas.
  • Vitrakvi, a first-in-class oral TRK inhibitor developed and commercialized in collaboration with Bayer that was recently approved by the FDA. Vitrakvi is the first treatment that targets a specific genetic abnormality to receive a tumour-agnostic indication at the time of initial FDA approval.
  • LOXO-195, a follow-on TRK inhibitor also being studied by Loxo Oncology and Bayer for acquired resistance to TRK inhibition, with a potential launch in 2022.
  • "Using tailored medicines to target key tumour dependencies offers an increasingly robust approach to cancer treatment," said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories. "Loxo Oncology's portfolio of RET, BTK and TRK inhibitors targeted specifically to patients with mutations or fusions in these genes, in combination with advanced diagnostics that allow us to know exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer."

    "We are gratified that Lilly has recognized our contributions to the field of precision medicine and are excited to see our pipeline benefit from the resources and global reach of the Lilly organization," said Josh Bilenker, CEO of Loxo Oncology. "Tumour genomic profiling is becoming standard-of-care, and it will be critical to continue innovating against new targets, while anticipating mechanisms of resistance to available therapies, so that patients with advanced cancer have the chance to live longer and better lives."

    "Lilly Oncology is committed to developing innovative, breakthrough medicines that will make a meaningful difference for people with cancer and help them live longer, healthier lives," said Anne White, president of Lilly Oncology. "The acquisition of Loxo Oncology represents an exciting and immediate opportunity to expand the breadth of our portfolio into precision medicines and target cancers that are caused by specific gene abnormalities. The ability to target tumor dependencies in these populations is a key part of our Lilly Oncology strategy. We look forward to continuing to advance the pioneering scientific innovation begun by Loxo Oncology."

    "We are excited to have reached this agreement with a team that shares our commitment to ensuring that emerging translational science reaches patients in need," said Jacob Van Naarden, chief operating officer of Loxo Oncology. "We are confident that the work we have started, which includes an FDA approved drug, and a pipeline spanning from Phase II to discovery, will continue to thrive in Lilly's hands."

    Read More

    Related tags

    Market News

    Related news

    Specialist API CDMO acquired by GHO Capital

    Specialist API CDMO acquired by GHO Capital

    16 Mar 2019

    Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.

    Read more 
    Bringing next generation single-use sensor technologies to the life science market

    Bringing next generation single-use sensor technologies to the life science market

    14 Mar 2019

    Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.

    Read more 
    Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

    Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

    13 Mar 2019

    Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

    Read more 
    TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

    TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

    12 Mar 2019

    Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.

    Read more 
    Overcoming lyophilization challenges at Interphex 2019

    Overcoming lyophilization challenges at Interphex 2019

    10 Mar 2019

    Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.

    Read more 
    Catalent invests over $27 million to commercialize Zydis Ultra

    Catalent invests over $27 million to commercialize Zydis Ultra

    7 Mar 2019

    Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.

    Read more 
    Novel systems for membrane chromatography

    Novel systems for membrane chromatography

    6 Mar 2019

    Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.

    Read more 
    Lilly to introduce lower-priced insulin

    Lilly to introduce lower-priced insulin

    5 Mar 2019

    Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.

    Read more 
    Biogen acquisition boosts its ophthalmology pipeline

    Biogen acquisition boosts its ophthalmology pipeline

    4 Mar 2019

    Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

    Read more 
    Uniqsis expands LED photoreactor range

    Uniqsis expands LED photoreactor range

    3 Mar 2019

    The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

    Read more